These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38795804)

  • 41. Defining the scope of health technology assessment and types of health economic evaluation.
    Tanvejsilp P; Ngorsuraches S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S10-6. PubMed ID: 24964694
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expanding Health Technology Assessments to Include Effects on the Environment.
    Marsh K; Ganz ML; Hsu J; Strandberg-Larsen M; Gonzalez RP; Lund N
    Value Health; 2016; 19(2):249-54. PubMed ID: 27021760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis.
    Basu S; Bendavid E; Sood N
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):541-51. PubMed ID: 26555122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Defining quality health care with outcomes assessment while achieving economic value.
    Shaw LJ; Miller DD
    Top Health Inf Manage; 2000 Feb; 20(3):44-54. PubMed ID: 10747434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Could or Should We Use MCDA in the French HTA Process?
    Ghabri S; Josselin JM; Le Maux B
    Pharmacoeconomics; 2019 Dec; 37(12):1417-1419. PubMed ID: 31565761
    [No Abstract]   [Full Text] [Related]  

  • 46. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program.
    Tantivess S; Teerawattananon Y; Mills A
    Pharmacoeconomics; 2009; 27(11):931-45. PubMed ID: 19888793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?
    Culyer AJ; Chalkidou K
    Value Health; 2019 Jan; 22(1):99-103. PubMed ID: 30661640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health Technology Assessment: managing the introduction and use of medical devices in clinical practice in Italy.
    Migliore A; Ratti M; Cerbo M; Jefferson T
    Expert Rev Med Devices; 2009 May; 6(3):251-7. PubMed ID: 19419283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?
    Tarricone R; Torbica A; Ferré F; Drummond M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):707-18. PubMed ID: 25196848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive league table of cost-utility ratios: A systematic review of cost-effectiveness evidence for health policy decisions in India.
    Shah K; Singh M; Kotwani P; Tyagi K; Pandya A; Saha S; Saxena D; Rajshekar K
    Front Public Health; 2022; 10():831254. PubMed ID: 36311623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Health economics and HTA].
    Kulp W; Greiner W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):257-63. PubMed ID: 16465516
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review.
    Farah L; Borget I; Martelli N; Vallee A
    J Med Internet Res; 2024 May; 26():e51514. PubMed ID: 38739911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review.
    Gheorghe A; Griffiths U; Murphy A; Legido-Quigley H; Lamptey P; Perel P
    BMC Public Health; 2018 Aug; 18(1):975. PubMed ID: 30081871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The economic evaluation of medical devices: challenges ahead.
    Kirisits A; Redekop WK
    Appl Health Econ Health Policy; 2013 Feb; 11(1):15-26. PubMed ID: 23329383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ten recommendations for assessing the comparative effectiveness of therapeutic medical devices: a targeted review and adaptation.
    Schnell-Inderst P; Hunger T; Conrads-Frank A; Arvandi M; Siebert U
    J Clin Epidemiol; 2018 Feb; 94():97-113. PubMed ID: 29107757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The main methodological aspects in Health Technology Assessment].
    Vallejos C; Bustos L; de la Puente C; Reveco R; Velásquez M; Zaror C
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S16-21. PubMed ID: 24861175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic evaluation of diagnostic technology. Methodological challenges and viable solutions.
    Sassi F; McKee M; Roberts JA
    Int J Technol Assess Health Care; 1997; 13(4):613-30. PubMed ID: 9489253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease.
    Burgers LT; Redekop WK; Severens JL
    Pharmacoeconomics; 2014 Jul; 32(7):627-37. PubMed ID: 24748448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.